Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: Virus persists and spreads systemically at late time points

Human Gene Therapy

Volumn 14, Issue 5, 2003, Pages 425-433

  Sauthoff, Harald ^a   Hu, Jing ^a   Maca, Cielo ^a   Goldman, Michael ^a   Heitner, Sheila ^a   Yee, Herman ^a   Pipiya, Teona ^a   Rom, William N ^a   Hay, John G ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VIRUS; RECOMBINANT DNA; REPETITIVE DNA; VIRUS DNA; VIRUS VECTOR;

ADENOVIRUS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONNECTIVE TISSUE; CONTROLLED STUDY; DNA HYBRIDIZATION; DNA PROBE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KINETICS; MOUSE; NONHUMAN; PERSISTENT VIRUS INFECTION; TUMOR NECROSIS; TUMOR XENOGRAFT; VASCULARIZATION; VIRAL GENE THERAPY; VIRUS REPLICATION; VIRUS TITRATION;

ADENOVIRIDAE; ANIMALS; CELL LINE, TRANSFORMED; CONNECTIVE TISSUE; DNA PROBES; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS; KINETICS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; TUMOR CELLS, CULTURED; VIRUS REPLICATION; VON WILLEBRAND FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; MURINAE;

EID: 0037457032     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303403321467199     Document Type: Article

References (22)

1. ALEMANY, R., SUZUKI, K., and CURIEL, D.T. (2000). Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol. 81(Pt 11), 2605-2609.
2. BETT, A.J., KROUGLIAK, V., and GRAHAM, F.L. (1995). DNA sequence of the deletion/insertion in early region 3 of Ad5 d1309. Virus Res. 39, 75-82.
3. BLAIR, G.E., DIXON, S.C., GRIFFITHS, S.A, and ZAJDEL, M.E. (1989). Restricted replication of human adenovirus type 5 in mouse cell lines. Virus Res. 14, 339-346.
4. CURIEL, D.T. (2000). The development of conditionally replicative adenoviruses for cancer therapy. Clin. Cancer Res. 6, 3395-3399.
5. DEWEESE, T.L., VAN DER POEL, H., LI, S., MIKHAK, B., DREW, R., GOEMANN, M., HAMPER, U., DEJONG, R., DETORIE, N., RODRIGUEZ, R., HAULK, T., DEMARZO, A.M., PIANTADOSI, S., YU, D.C., CHEN, Y., HENDERSON, D.R., CARDUCCI, M.A., NELSON, W.G., and SIMONS, J.W. (2001). A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 61, 7464-7472.
6. DORONIN, K., TOTH, K., KUPPUSWAMY, M., WARD, P., TOLLEFSON, A.E., and WOLD, W.S. (2000). Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J. Virol. 74, 6147-6155.
7. DOUGLAS, J.T., KIM, M., SUMEREL, L.A., CAREY, D.E., and CURIEL, D.T. (2001). Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res. 61, 813-817.
8. GRAHAM, F.L., and PREVEC, L. (1995). Methods for construction of adenovirus vectors. Mol. Biotechnol. 3, 207-220.
9. HARRISON, D., SAUTHOFF, H., HEITNER, S., JAGIRDAR, J., ROM, W.N., and HAY, J.G. (2001). Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved - deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. Hum. Gene Ther. 12, 1323-1332.
10. HEISE, C.C., WILLIAMS, A.M., XUE, S., PROPST, M., and KIRN, D.H. (1999). Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res. 59, 2623-2628.
11. JOHNSON, L., SHEN, A., BOYLE, L., KUNICH, J., PANDEY, K., LEMMON, M., HERMISTON, T., GIEDLIN, M., MCCORMICK, F., and FATTAEY, A. (2002). Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 1, 325-337.
12. KHURI, F.R., NEMUNAITIS, J., GANLY, I., ARSENEAU, J., TANNOCK, I.F., ROMEL, L., GORE, M., IRONSIDE, J., MACDOUGALL, R.H., HEISE, C., RANDLEV, B., GILLENWATER, A.M., BRUSO, P., KAYE, S.B., HONG, W.K., and KIRN, D.H. (2000). a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer [see comments]. Nat. Med. 6, 879-885.
13. KIRN, D., MARTUZA, R.L., and ZWIEBEL, J. (2001). Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat. Med. 7, 781-787.
14. KURIHARA, T., BROUGH, D.E., KOVESDI, I., and KUFE, D.W. (2000). Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J. Clin. Invest. 106, 763-771.
15. LI, Y., PONG, R.C., BERGELSON, J.M., HALL, M.C., SAGALOWSKY, A.I., TSENG, C.P., WANG, Z., and HSIEH, J.T. (1999). Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy. Cancer Res. 59, 325-330.
16. MITTEREDER, N., MARCH, K.L., and TRAPNELL, B.C. (1996). Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70, 7498-7509.
17. NEMUNAITIS, J., KHURI, F., GANLY, I., ARSENEAU, J., POSNER, M., VOKES, E., KUHN, J., MCCARTY, T., LANDERS, S., BLACKBURN, A., ROMEL, L., RANDLEV, B., KAYE, S., and KIRN, D. (2001). Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19, 289-298.
18. SUZUKI, K., ALEMANY, R., YAMAMOTO, M., and CURIEL, D.T. (2002). The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin. Cancer Res. 8, 3348-3359.
19. TCHOU-WONG, K.M., JIANG, Y., YEE, H., LAROSA, J., LEE, T.C., PELLICER, A., JAGIRDAR, J., GORDON, T., GOLDBERG, J.D., and ROM, W.N. (2002). Lung-specific expression of dominant-negative mutant p53 in transgenic mice increases spontaneous and benzo(a)pyrene-induced lung cancer. Am. J. Respir. Cell Mol. Biol. 27, 186-193.
20. WILDNER, O., and MORRIS, J.C. (2000). The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: Assessment of antitumor efficacy and toxicity. Cancer Res. 60, 4167-4174.
21. WILDNER, O., MORRIS, J.C., VAHANIAN, N.N., FORD, H., Jr., RAMSEY, W.J., and BLAESE, R.M. (1999). Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther. 6, 57-62.
22. ZIETKIEWICZ, E., and LABUDA, D. (1996). Mosaic evolution of rodent B1 elements. J. Mol. Evol. 42, 66-72.